Diagnostics

Optherion is developing a genetic and biomarker platform that will identify individuals at risk of developing AMD, and predict the disease progression and treatment outcome in diagnosed patients.  Enhanced awareness of risk will provide actionable information upon which medical professionals can intervene more aggressively with recommended lifestyle changes, and facilitate advanced planning for available therapies.  Optherion has acquired an extensive portfolio of intellectual properties comprised of genetic and protein biomarkers associated with AMD.  Through an extensive R&D program and an active business development/licensing effort, Optherion aims to offer a best-in-class diagnostic platform for AMD.